Article |
2 Department of Biochemistry, Molecular Biology, and Cell Biology, Northwestern University, Evanston, IL 60208
Address correspondence to Robert A. Lamb, Dept. of Biochemistry, Molecular Biology, and Cell Biology, Northwestern University, 2205 Tech Drive, Evanston, IL 60208-3500. Tel.: (847) 491-5433. Fax: (847) 491-2467. email: ralamb{at}northwestern.edu
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: viral fusion proteins; membrane fusion activation; molecular models; protein conformation; antiviral agents
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Activation of most paramyxovirus F proteins at neutral pH is thought to be triggered by a three-step process including binding of the viral receptor-binding protein (RBP) HN or H to its receptor, HN interacting with F, and the HN/F interaction, leading to changes in F that mediate membrane fusion (Crennell et al., 2000; for review see Lamb and Kolakofsky, 2001; Russell et al., 2001; Takimoto et al., 2002; Colman and Lawrence, 2003). Most paramyxovirus F proteins require coexpression of their homotypic RBP for efficient fusion activity, and mutant RBPs have been discovered that retain receptor-binding activity, but have reduced or eliminated fusion-promotion activity (for review see Lamb and Kolakofsky, 2001). However, the SV5 W3A strain F protein mediates fusion when expressed alone, albeit to a lesser extent than when coexpressed with HN (Paterson et al., 1985). The anomalous HN-independent fusion activity of SV5 W3A strain F has been mapped to P22 near the NH2 terminus of F2 (Ito et al., 2000; Paterson et al., 2000; Tsurudome et al., 2001), and HN-independent fusion by NDV F results from an L289A mutation (Sergel et al., 2000) that is located on the NDV F atomic structure between the fusogenic and ß-barrel domains (Chen et al., 2001; Fig. 1). Moreover, the SV5 W3A strain F mutation S443P (in a region adjacent to HRB) has a hyperactive fusion phenotype (Paterson et al., 2000). The mechanisms by which these mutations lower the energy required to activate metastable F and their effects on F protein intermediates and fusogenic F are unclear.
High resolution structures have been determined for 6HBs formed by peptides derived from the HRA and HRB regions of the paramyxovirus F proteins from SV5 and HRSV F (Baker et al., 1999; Zhao et al., 2000). For SV5, the 6HB was formed by peptide N-1 containing all of HRA and part of the fusion peptide, and by peptide C-1 containing all of HRB and an extended chain region (Fig. 1). The trimer-of-heterodimer structures of these complexes share a remarkable similarity to those of other type I vFGps (Skehel and Wiley, 2000; Eckert and Kim, 2001), including prominent cavities in the HRA cores to which residues adjacent to HRB such as SV5 F L447 and I449 pack tightly (Fig. 1). As predicted by the continuation of the HRA coiled coil into the fusion peptide and the proximity of the HRB helices to the TM domain (Baker et al., 1999), experiments on the arrest and capture of SV5 F intermediates are consistent with the formation of the 6HB being coupled directly to membrane merger (Russell et al., 2001). The atomic structure of NDV F has been determined from a crystal consisting of a mixture of uncleaved F0 and cleaved F (cleaved at residue 139 in the fusion peptide region instead of the biological cleavage site at 117; Chen et al., 2001). Unfortunately, there is a lack of interpretable electron density for axial crystal contacts and for the fusion peptide, NH2-terminal half of HRA, and HRB regions. Therefore, the roles of the HR regions in the structural transitions of F during the fusion process remain unclear (Colman and Lawrence, 2003).
To understand the role of the cavity-binding residues in 6HB formation and F-mediated fusion, we mutated SV5 F residues L447 and I449 adjacent to HRB in SV5 F. Mutation of the HRA cavity-binding residues destabilizes the 6HB structure and decreases the inhibitory potency of SV5 C-peptides in a correlative manner. These results identify in the F protein the physical target of the potent C-1 inhibitory peptide. Unexpectedly, the effects of the L447 and I449 mutations on F protein activation were even more drastic than their effects on 6HB formation. Residues 447 and 449 are shown here to be critical determinants of the energetic threshold required for activation of metastable F. In fact, mutant F proteins containing aromatic mutations at L447 and I449 cause hyperactive fusion despite having reduced 6HB stabilities, thus displaying a novel phenotype in which 6HB stability does not correlate with fusogenicity. Combined with previous data from this paper showing that residue 443 is also critical in the activation of F, the present data show that the residues comprising a linear segment adjacent to HRB (including [but not limited to] residues 443, 447, and 449) regulate the stabilization and controlled activation of metastable F. Overall, the data are consistent with this linear segment having dual interaction sites in F, one in metastable F and one in the 6HB, thereby providing a key regulation of the precise switch between the metastable and fusion-active forms of the protein. We propose that other type I vFGps like HIV gp41 may have evolved similar dual-functional residues to control the precise switch between their native and fusogenic structures.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Most of the L447 and I449 mutations are tolerated in the full-length protein
We constructed the L447 and I449 mutants in the background of the F protein and expressed these F protein mutants using both the pGEM-VacT7 and pCAGGS expression systems (see Materials and methods). The expression levels of individual F mutants did not vary between the two expression systems (Table II). The percentage of cells transfected did not differ significantly between wt and mutant F proteins (unpublished data); however, the mean fluorescence intensity values of transfected cells varied significantly (Table II). The L447F and I449G mutations caused a large reduction in F protein cell surface expression levels relative to wt, perhaps due to misfolding or a transport defect. The F protein aromatic mutants L447W, I449F, and I449W had cell surface expression levels between 50 and 75% of wt. The F protein aliphatic mutants L447G, I449A, and I449L had expression levels of 6585% wt, and L447A, L447V, and L447I had expression levels similar to wt. Variable cell surface expression levels of the mutants requires quantitative membrane fusion assays to control for differential cell surface expression.
|
The F mutants show variable dependence on HN for fusion activation
To examine the abilities of the mutant F proteins to cause cellcell fusion, syncytium formation was examined. Representative photomicrographs of syncytium formation in BHK cells transfected with the F mutants are shown in Fig. 3 A. All of the mutants except I449G (which has a cell surface expression level <10% of wt) promoted syncytium formation when coexpressed with SV5 HN (Table III). In the presence of HN coexpression, I449A and I449V promoted syncytium formation less efficiently than wt F, whereas the remainder of the F proteins containing aliphatic mutations promoted syncytium formation similar to wt F. When coexpressed with HN, the F proteins containing aromatic mutations promoted larger syncytium formation than wt F (Fig. 3 A). Therefore, the effects of the L447 and I449 mutations on syncytium formation do not correlate with their effects on 6HB stability.
|
|
To quantify the fusion phenotypes of the mutants, we used a luciferase gene-reporter assay to measure content mixing. As the extent of fusion mediated by SV5 F is dependent on cell surface expression levels and the expression levels of the mutants varied, we first measured the luciferase activities resulting from various amounts of wt F cell surface expression, as indicated by the lines connecting the open squares in Fig. 3 (B and C). The fusion activity of wt F as a function of expression in the presence and absence of HN coexpression is reported in Fig. 3 (B and C, respectively). In the presence of HN coexpression, the F proteins containing aliphatic mutations had fusion activities similar to wt when compared with equivalent expression levels (Fig. 3 B). However, F proteins containing aliphatic mutations were much less efficient than wt in causing fusion in the absence of HN coexpression (Fig. 3 C). In contrast, the F proteins containing aromatic mutations had fusion-hyperactive phenotypes both in the presence and absence of HN coexpression (Fig. 3, B and C; points above the lines). These results are consistent with the syncytia and mAb 21-1binding analyses (Table II).
The F mutants are not blocked in a prehairpin conformation or in a form that only causes hemifusion
The L447 and I449 mutations in C-1 reduce 6HB stability (Table I; Fig. 2), and the available data indicate that 6HB formation is coupled directly to membrane merger (Russell et al., 2001). In principle, the reduction in fusion activity by the F proteins containing aliphatic mutations could be due to a decrease in energy released per 6HB given a fixed number of activated trimers. If this were the case, fusion might be arrested at either a hemifusion stage (characterized by the ability to promote lipid but not content mixing; Melikyan et al., 1999; Armstrong et al., 2000) or after formation of a target membraneinserted prehairpin intermediate (characterized by the ability to retain bound RBCs independent of HN; Russell et al., 2001). To test the effects of the mutations on late steps in fusion, we performed a dye transfer assay for fusion using dual-labeled (lipidic R18 and aqueous carboxyfluorescein [CF]) RBCs. There were no significant differences between the extents of transfer of R18 lipidic dye and CF aqueous dye for any individual mutant, whether coexpressed with SV5 HN or when coexpressed with uncleaved influenza virus HA (fusion inactive) as a binding protein (Table III). Therefore, the mutants do not exhibit a hemifusion phenotype. Consistent with the results obtained from syncytia analysis and from the luciferase assay, the F proteins containing aliphatic mutations had a great reduction in dye transfer in the absence of HN coexpression.
Unexpectedly, we found the F proteins containing aromatic mutations L447F and L447W did not promote dye transfer, and that I449F and I449W promoted dye transfer inefficiently. To address the apparent anomaly of these mutants having a fusion-hyperactive phenotype in syncytium formation and the luciferase assay, but a fusion-deficient phenotype in the dye transfer assay, we performed the dye-transfer assay using CF-labeled RBC target cells and SYTO-17labeled CV-1 effector cells. With the modified assay, both syncytium formation by CV-1 effector cells and dye transfer from RBC target cells were visualized simultaneously. Moreover, the differential labeling of CV-1 cells and RBCs also allows for analysis of F-dependent retention of target RBCs resulting from a prehairpin conformation of the F protein that is likely anchored to both cell membranes through the TM and fusion peptide regions (Russell et al., 2001). Incubation of the effectortarget cell complexes at 37°C resulted either in dye transfer or the release of unfused RBCs (due to a decrease in affinity of HN for its receptor sialic acid upon heating at 37°C; Corey et al., 2003; Fig. 4). The lack of F-dependent RBC retention by mutants with inefficient dye transfer is consistent with the mutations affecting an F protein intermediate preceding prehairpin formation (Russell et al., 2001), and not due to differential binding of RBCs because all of the mutant F proteins bound similar numbers of RBCs (unpublished data). Differential levels of syncytium formation occurred between CV-1 cells expressing HN and the F mutants before incubation of effectortarget cell complexes at 37°C (unpublished data), as can be seen in the images collected after 37°C incubation (Fig. 4). The large syncytia formed between cells coexpressing HN and the F proteins containing aromatic mutations (Fig. 4, arrows) indicates these mutations cause the F proteins to exhibit a hyperactive fusionpromotion ability after reaching the cell surface, provided target cells are proximal. However, the lack of efficient dye transfer after 18 h incubation at 33°C before target RBC coincubation for 1 h at 4°C and 15 min incubation at 37°C is completely consistent with these F proteins containing aromatic mutations becoming inactivated in the absence of fusion targets. It should be noted that for the luciferase assay, the transiently transfected Vero cells were incubated for 18 h at 37°C before target T7-BSR cell coincubation for 8 h at 37°C, so that the combination of a long coincubation time (8 h vs. 15 min) and continuous (further) expression of the F protein mutants did not reveal the "do-or-die" phenotype of the F proteins containing aromatic mutations that was observed in the RBC dye-transfer assay. Additionally, Vero cells were specifically chosen for the luciferase assay because Vero cells do not form syncytia after 18 h of transient transfection with the F protein mutants, whereas transiently transfected BHK cells and infected/transfected CV1 cells do form syncytia 18 h after transfection. The fusion-hyperactive S443P mutant did not become inactivated under the conditions of the RBC dye-transfer assay (Table III), suggesting that the hyperactive fusion phenotype of the aromatic mutations at L447 and I449 differs from that of S443P, despite both S443P and the aromatic mutations at L447 and I449 having increased reactivity to mAb 21-1, increased syncytium formation, and increased luciferase activity.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Unexpectedly, the effects of the mutations on fusion activation appear to be greater than their effects on 6HB formation. The F proteins containing aromatic mutations form less stable 6HBs than wt F (Fig. 2), thereby coupling less energy to fusion per 6HB. The hyperactive phenotype of the F proteins containing aromatic mutations is consistent with these mutations destabilizing the F protein native metastable state so that more trimers become activated (Fig. 7 B). In contrast, it seems most likely that the F proteins containing aliphatic mutations have both higher energetic requirements for activation and lower amounts of energy per 6HB to couple to fusion (Fig. 7 B). For the F proteins containing the aliphatic mutations, the decrease in fusion activity is most likely due to the combination of decreases in the number of activated trimers and the amount of energy released per 6HB. The fusion deficiencies of the aliphatic mutants cannot be due to their reduced 6HB stabilities alone because the aliphatic mutants were restricted at fusion activation and not at prehairpin or hemifusion intermediate formation.
To avoid inactivation, the native metastable structures of the type I vFGps must prevent indiscriminate release of the fusion peptide and HR regions until the target membranes are within range. A general strategy for a tightly regulated fusion mechanism may include sequences within or near HR regions having dual structural roles; one in the native structure to regulate fusion activation and another in the final structure to determine hairpin stability. The linear segment from 443 to 449, adjacent to HRB, in the paramyxovirus F protein has been shown here to be critical in stabilizing both the native and fusogenic forms of the protein. Moreover, mutational analyses on HIV gp41mediated fusion have identified individual HRA and HRB residues critical in the stabilization of both the native gp120gp41 complex and the 6HB structure (Lu et al., 2001; Follis et al., 2002; Sanders et al., 2002). The strongest evidence for HR residues with dual, independent interaction sites comes from structural and genetic experiments on influenza virus HA. Numerous HRA residues in HA2 (in segments A and C) bind to other HRA residues in the native structure, but interact with the antiparallel buttressing strand (equivalent to a HRB region) in the fusogenic structure (Daniels et al., 1987; Bullough et al., 1994; Chen et al., 1999). Other residues identified as critical in the switch between the native and fusogenic structures of HA2 include those in and around the fusion peptide and those involved in interactions between HA2 and HA1 (Bullough et al., 1994), showing regions other than the HR regions may be critical in stabilizing the native states of other type I vFGps. Further structural and biochemical analyses on the native metastable forms of these proteins will be instrumental in better understanding the general principles governing type I fusion activation and its inhibition.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Biophysical characterization of peptide 6HBs
Appropriate volumes of 6HBs were formed by mixing peptide stock solutions to yield a final concentration of 10 µM of each peptide in PBS (50 mM phosphate buffer, pH 7.0, and 150 mM NaCl) and dialyzing the mixtures twice against 4 l PBS. Sedimentation equilibria were measured at 20°C after a 24-h centrifugation at 15,000, 20,000 and 25,000 rpm using an analytical ultracentrifuge (model XL-A; Beckman Coulter). The apparent mol wts of the complexes were determined by fitting to a single-ideal species model using Igor Pro (Wavemetrics). Circular dichroism experiments on 6HB solutions (10 µM of each peptide in PBS) were performed using a spectropolarimeter (model J-715; Jasco) as described previously (Joshi et al., 1998).
Expression of viral envelope glycoproteins
Viral envelope glycoproteins were expressed using two different expression systems: (a) Vero or BHK cells transfected with pCAGGS DNA and (b) CV-1 cells infected with the recombinant vaccinia virus vTF7-3 and transfected with pGEM DNA. Vero and BHK cells were transfected using the LipofectAMINETM Plus expression system according to the manufacturer's instructions (Invitrogen). Transfected Vero and BHK cells were incubated for 4 h at 37°C before adding DME containing 10% FBS and incubating 18 h at 37°C. CV-1 cells were infected with vTF7-3 and transfected with pGEM DNA as described previously (Paterson et al., 2000). Transfected CV-1 cells were incubated for 4 h at 37°C before adding DME containing 10% FBS and incubating for 18 h at 33°C. Metabolic labeling was performed as described previously (Paterson and Lamb, 1993) with a 15-min pulse labeling (35S-Promix, 50 µCi/well; Amersham Biosciences) and a 3-h chase. Immunoprecipitations were performed using an antibody specific for F2. Quantification was done using a bioimage analyzer (BAS1000; Fuji). Flow cytometric experiments were performed as described previously (Paterson et al., 2000) using mAb F1a at a 1:200 dilution (Paterson et al., 2000) or mAb 21-1 at a 1:100 dilution (Tsurudome et al., 2001).
Syncytium formation
Monolayers of BHK 21F cells were transfected with F DNA alone or with F and HN DNA as described above. Syncytia were photographed 20 h after transfection with a digital camera (DCS 760; Kodak) attached to an inverted phase-contrast microscope (Diaphot; Nikon).
Luciferase reporter gene assay for content mixing
Vero cells were transfected with Luciferase Control DNA (Promega), pCAGGS SV5 F, and pCAGGS HN (or HA) as described above. 18 h after transfection, BSR cells (expressing T7 RNA polymerase) were removed from T75 flasks and overlaid onto the Vero cells. After a 6-h incubation at 37°C, the monolayers were washed twice with PBS-, overlaid with 100 µl Reporter Lysis Buffer (Promega), lysed by freeze-thawing, and clarified by centrifugation at 14,000 rpm in an Eppendorf microcentrifuge. From each clarified lysate, 40 µl solution was pipetted into a 96-well plate. The luciferase activity resulting from fusion of the two-cell populations was quantified using Luciferase Assay Substrate (Promega) and an Lmax luminescence microplate reader (Molecular Devices). For peptide inhibition experiments, BSR cells were aliquoted into Eppendorf tubes containing twofold serial dilutions of C-peptides before being overlaid onto the Vero cells. The IC50 values of the peptides were estimated by fitting the experimental data to the equation y = 100 - 100 x [(x/a) ^ k/(1 + [x/a] ^ k)], where y is average percentage of luciferase activity (from triplicate samples), x is the bulk concentration of peptide, k is a scaling constant, and a is the IC50 value.
Lipidic and aqueous dye transfer
Human erythrocytes (RBCs) were single labeled with aqueous 6-CF (Molecular Probes, Inc.) or dual labeled with CF and the lipid probe octadecyl rhodamine B chloride (R18; Molecular Probes). CV-1 cells grown on glass coverslides were infected with vTF7-3 and transfected with pGEM DNA for 4 h at 37°C, followed by 18 h at 33°C. To allow binding of the dye-labeled RBCs but to prevent temperature-induced fusion, 1 ml ice-cold 0.1% hematocrit dye-labeled RBCs was added to each sample and the CV-1/RBC (effectortarget) complexes were incubated on ice at 4°C for 1 h. The effectortarget cell complexes were incubated at 37°C for 15 min to allow dye transfer to take place, before washing five times with ice-cold PBS+ to remove unbound RBCs. Dye transfer was assessed by scanning confocal microscopy (model LSM 410; Carl Zeiss MicroImaging, Inc.) and quantifying CF or R18 dye transfer from labeled RBCs to CV-1 cells. To study syncytium formation and HN-independent retention of RBCs, CV-1 effector cells were labeled with 1 µM SYTO-17 nucleic acid dye (Molecular Probes, Inc.) at 37°C for 30 min, and single-labeled CF-RBCs were used as fusion targets. For the temperature dependence of dye transfer, effectortarget complexes were incubated for 5 min at the reported temperatures before washing with ice-cold PBS+. For the kinetics of dye transfer, effectortarget complexes were incubated at 37°C for the reported times before washing with ice-cold PBS+.
![]() |
Acknowledgments |
---|
This work was supported in part by research grant AI-23173 from the National Institute of Allergy and Infectious Disease. C.J. Russell is an Associate and R.A. Lamb is an Investigator of the Howard Hughes Medical Institute.
Submitted: 28 May 2003
Accepted: 15 September 2003
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Armstrong, R.T., A.S. Kushnir, and J.M. White. 2000. The transmembrane domain of influenza hemagglutinin exhibits a stringent length requirement to support the hemifusion to fusion transition. J. Cell Biol. 151:425437.
Baker, K.A., R.E. Dutch, R.A. Lamb, and T.S. Jardetzky. 1999. Structural basis for paramyxovirus-mediated membrane fusion. Mol. Cell. 3:309319.[Medline]
Buckland, R., E. Malvoisin, P. Beauverger, and F. Wild. 1992. A leucine zipper structure present in the measles virus fusion protein is not required for its tetramerization but is essential for fusion. J. Gen. Virol. 73:17031707.[Abstract]
Bullough, P.A., F.M. Hughson, J.J. Skehel, and D.C. Wiley. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 371:3743.[CrossRef][Medline]
Calder, L.J., L. Gonzalez-Reyes, B. Garcia-Barreno, S.A. Wharton, J.J. Skehel, D.C. Wiley, and J.A. Melero. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology. 271:122131.[CrossRef][Medline]
Chan, D.C., C.T. Chutkowski, and P.S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA. 95:1561315617.
Chen, J., J.J. Skehel, and D.C. Wiley. 1999. N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA2 subunit to form an N cap that terminates the triple-stranded coiled coil. Proc. Natl. Acad. Sci. USA. 96:89678972.
Chen, L., J.J. Gorman, J. McKimm-Breschkin, L.J. Lawrence, P.A. Tulloch, B.J. Smith, P.M. Colman, and M.C. Lawrence. 2001. The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure. 9:255266.[CrossRef][Medline]
Colman, P.M., and M.C. Lawrence. 2003. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4:309319.[CrossRef][Medline]
Corey, E.A., A.M. Mirza, E. Levandowsky, and R.M. Iorio. 2003. Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding. J. Virol. 77:69136922.
Crennell, S., T. Takimoto, A. Portner, and G. Taylor. 2000. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat. Struct. Biol. 7:10681074.[CrossRef][Medline]
Daniels, P.S., S. Jeffries, P. Yates, G.C. Schlid, G.N. Rogers, J.C. Paulson, S.A. Wharton, A.R. Douglas, J.J. Skehel, and D.C. Wiley. 1987. The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-hemagglutinin monoclonal antibodies. EMBO J. 6:14591465.[Abstract]
Eckert, D.M., and P.S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777810.[CrossRef][Medline]
Follis, K.E., S.J. Larson, M. Lu, and J.H. Nunberg. 2002. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J. Virol. 76:73567362.
Hernandez, L.D., L.R. Hoffman, T.G. Wolfsberg, and J.M. White. 1996. Virus-cell and cell-cell fusion. Annu. Rev. Cell Dev. Biol. 12:627661.[CrossRef][Medline]
Ito, M., M. Nishio, H. Komada, Y. Ito, and M. Tsurudome. 2000. An amino acid in the heptad repeat 1 domain is important for the haemagglutinin-neuraminidase-independent fusing activity of simian virus 5 fusion protein. J. Gen. Virol. 81:719727.
Joshi, S.B., R.E. Dutch, and R.A. Lamb. 1998. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology. 248:2034.[CrossRef][Medline]
Lamb, R.A., and D. Kolakofsky. 2001. Paramyxoviridae: the viruses and their replication. Fields Virology. 2nd ed. D.M. Knipe and P.M. Howley, editors. Lippincott, Williams and Wilkins, Philadelphia. 13051340.
Lu, M., M.O. Stoller, S. Wang, J. Liu, M.B. Fagan, and J.H. Nunberg. 2001. Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J. Virol. 75:1114611156.
McGinnes, L.W., T. Sergel, H. Chen, L. Hamo, S. Schwertz, D. Li, and T.G. Morrison. 2001. Mutational analysis of the membrane proximal heptad repeat of the Newcastle disease virus fusion protein. Virology. 289:343352.[CrossRef][Medline]
Melikyan, G.B., S. Lin, M.G. Roth, and F.S. Cohen. 1999. Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Mol. Biol. Cell. 10:18211836.
Melikyan, G.B., R.M. Markosyan, H. Hemmati, M.K. Delmedico, D.M. Lambert, and F.S. Cohen. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413423.
Paterson, R.G., S.W. Hiebert, and R.A. Lamb. 1985. Expression at the cell surface of biologically active fusion and hemagglutinin-neuraminidase proteins of the paramyxovirus simian virus 5 from cloned cDNA. Proc. Natl. Acad. Sci. USA. 82:75207524.[Abstract]
Paterson, R.G., and R.A. Lamb. 1993. The molecular biology of influenza viruses and paramyxoviruses. Molecular Virology: A Practical Approach. A. Davidson and R.M. Elliott, editors. IRL Oxford University Press, Oxford. 3573.
Paterson, R.G., C.J. Russell, and R.A. Lamb. 2000. Fusion protein of the paramyxovirus SV5: destabilizing and stabilizing mutants of fusion activation. Virology. 270:1730.[CrossRef][Medline]
Ruigrok, R.W.H., S.R. Martin, S.A. Wharton, J.J. Skehel, P.M. Bayley, and D.C. Wiley. 1986. Conformational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes. Virology. 155:484497.[Medline]
Russell, C.J., T.S. Jardetzky, and R.A. Lamb. 2001. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J. 20:40244034.
Sanders, R.W., M. Vesanen, N. Schuelke, A. Master, L. Schiffner, R. Kalyanaraman, M. Paluch, B. Berkhout, P.J. Maddon, W.C. Olson, et al. 2002. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76:88758889.
Sergel, T.A., L.W. McGinnes, and T.G. Morrison. 2000. A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion. J. Virol. 74:51015107.
Sergel, T.A., L.W. McGinnes, and T.G. Morrison. 2001. Mutations in the fusion peptide and adjacent heptad repeat inhibit folding or activity of the Newcastle disease virus fusion protein. J. Virol. 75:79347943.
Skehel, J.J., and D.C. Wiley. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531569.[CrossRef][Medline]
Takimoto, T., G.L. Taylor, H.C. Connaris, S.J. Crennell, and A. Portner. 2002. Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. J. Virol. 76:1302813033.
Tsurudome, M., M. Ito, M. Nishio, M. Kawano, H. Komada, and Y. Ito. 2001. Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface. J. Virol. 75:89999009.
Ward, C.D., R.G. Paterson, and R.A. Lamb. 1995. Mutants of the paramyxovirus SV5 fusion protein: regulated and extensive syncytium formation. Virology. 209:242249.[CrossRef][Medline]
Wharton, S.A., J.J. Skehel, and D.C. Wiley. 2000. Temperature dependence of fusion by Sendai virus. Virology. 271:7178.[CrossRef][Medline]
Zhao, X., M. Singh, V.N. Malashkevich, and P.S. Kim. 2000. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA. 97:1417214177.